EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD : What we have accomplished and what opportunities lie ahead

Claire Horgan iD, Kelly Watts, Dipak Ram, Stewart Rust, Rebekah Hutton, Simon Jones, Rob Wynn

JIMD Reports · 2023-09 · 64 (5) · 346-352

DOI: 10.1002/jmd2.12378 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift JIMD Reports, online erschienen am 22.06.2023. Verfasst von Claire Horgan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Royal Manchester Children's Hospital Manchester University NHS Foundation Trust Manchester UK. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metachromatic leukodystrophy (MLD) results from ARSA gene mutations. Affected individuals meet early milestones before neurological deterioration and early death. Atidarsagene autotemcel (arsa‐cel), an autologous haematopoietic stem cell gene therapy (HSC‐GT) product, has demonstrated sustained clinical benefits in MLD. Arsa‐cel was approved for NHS treatment in February 2022 for asymptomatic late infantile or early juvenile disease, or early symptomatic early juvenile MLD. We evaluate the impact of this approval in the largest real‐world dataset of MLD HSC‐GT. Hospital records were reviewed for all patients referred for NHS treatment following arsa‐cel approval. Information was gathered about disease phenotype, presentation, eligibility, and affected siblings. In the year following NHS approval, 17 UK MLD patients were referred for treatment. Four patients met eligibility criteria and have been treated, including 1 infant who weighed 5 kg at leukapheresis. Eleven patients failed screening: 10 symptomatic patients with late infantile disease and 1 with early juvenile disease and cognitive decline. Two further patients with later onset subtypes did not meet the approval criteria. Three out of four treated patients were diagnosed by screening after MLD was diagnosed in a symptomatic older sibling. The success of HSC‐GT for MLD has heralded a new era of hope for families affected by this devastating disease, yet currently, most patients are ineligible for treatment at diagnosis. The feasibility of apheresis in infants and the availability of a licenced, effective HSC‐GT product highlights the urgent need for newborn screening to ensure that patients can be diagnosed and treated before symptom onset.

Schlagwörter

Stichwörter der Autor:innen

gene therapymetachromatic leukodystrophynewborn screeningtransplant

Autor:innen und Institutionen

  • Royal Manchester Children's Hospital Manchester University NHS Foundation Trust Manchester UK.

ORCID-Profile: Claire Horgan

Zitieren

APA

Horgan, C., Watts, K., Ram, D., Rust, S., Hutton, R., Jones, S., & Wynn, R. (2023). A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD : What we have accomplished and what opportunities lie ahead. JIMD Reports, 64(5), 346-352. https://doi.org/10.1002/jmd2.12378

Vancouver

Horgan C, Watts K, Ram D, Rust S, Hutton R, Jones S, et al. A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD : What we have accomplished and what opportunities lie ahead. JIMD Reports. 2023;64(5):346-352. doi:10.1002/jmd2.12378

BibTeX
@article{Horgan2023,
  author = {Horgan, Claire and Watts, Kelly and Ram, Dipak and Rust, Stewart and Hutton, Rebekah and Jones, Simon and Wynn, Rob},
  title = {A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD : What we have accomplished and what opportunities lie ahead},
  journal = {JIMD Reports},
  year = {2023},
  volume = {64},
  number = {5},
  pages = {346--352},
  doi = {10.1002/jmd2.12378}
}
Kostenlos starten →